VIP
Vasoactive Intestinal Peptide (VIP)
A 28-amino acid neuropeptide with potent anti-inflammatory, immunomodulatory, and bronchodilatory properties. Used in CIRS (Chronic Inflammatory Response Syndrome) treatment protocols.
Mechanism of Action
VIP binds to VPAC1 and VPAC2 receptors, activating cAMP pathways that suppress pro-inflammatory cytokines (TNF-α, IL-6, IL-12) and promote anti-inflammatory mediators. It also acts as a bronchodilator and vasodilator.
Health Claims & Evidence
Potent anti-inflammatory and immunomodulatory effects
Effective in CIRS and mold illness protocols
Bronchodilatory effects in respiratory conditions
Short-Term Effects
Reduced inflammatory symptoms, improved respiratory function, enhanced energy.
Long-Term Effects
Sustained reduction in inflammatory markers and symptom improvement in CIRS.
Side Effects
Generally well-tolerated intranasally. Mild nasal irritation. Hypotension at high doses.
Contraindications
Not recommended without addressing underlying environmental triggers in CIRS.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
VIP in inflammatory disease
Delgado et al. · Nature Reviews Immunology · 2004
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on VIP and related peptides, and prepare an educational research summary.
Explore Research